ALK-positive bone cancer treatment with targeted drugs
Treatments studied
Part of Bones, joints & muscles, Cancer clinical trials.
This trial tests two targeted drugs (crizotinib or alectinib) for advanced bone cancers with an ALK gene change. These drugs are designed to block a specific protein that helps cancer cells grow, and may help if standard treatments haven't worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 20 or older
- Advanced or spread bone cancer with ALK gene alteration confirmed by testing
- Cancer has grown despite standard treatment or no standard treatment is available
- At least one tumor that can be measured on scans
- Good enough overall health to tolerate treatment (ECOG score 0–2)
- Expected to live at least 8 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether ALK-targeted drugs can shrink or control advanced squamous cell cancer that has spread. You may be eligible if your tumor has an ALK gene rearrangement and you have not had prior cancer medicines for this stage.
This early-phase trial studies how alectinib (an ALK-blocking medicine) moves through the body and how it’s tolerated in people with advanced non-small cell lung cancer (NSCLC) that has an ALK rearrangement. You may be considered if you have ALK-positive, recurrent or advanced disease and have already had specific prior treatments.
This study tests whether alectinib can treat ALK-positive cancers in adults, teenagers, and children. It focuses on people whose cancer testing shows an ALK change, and who can start oral treatment and have a new tissue sample.
This trial tests giving alectinib first, then adding targeted radiation to remaining spots of cancer in people with ALK-rearranged advanced non-small cell lung cancer. It aims to control the cancer after an initial response and help keep disease from progressing.
This trial tests whether giving alectinib (a targeted drug) combined with chemotherapy before surgery can help people with stage III ALK-positive lung cancer that cannot be removed surgically. The goal is to shrink the tumor enough to make surgery possible and improve long-term outcomes.
This trial compares a new targeted pill (SY-3505) to the current standard drug (crizotinib) as a first treatment for people with advanced ALK-positive non-small cell lung cancer (NSCLC). It aims to find out which drug works better and has fewer side effects.
Hear when a new Bone Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.